PROTAC BET Degrader-17
PROTAC BET Degrader-17 is a potent BET protein PROTAC degrader. By recruiting the VHL E3 ligase, PROTAC BET Degrader-17 specifically degrades BRD2, BRD3 (DC50=0.09 nM) and BRD4 (IC50=4.3 nM). PROTAC BET Degrader-17 exhibits strong anti-tumor activity in acute myeloid leukemia (AML) studies; it not only inhibits cancer cell proliferation, induces cell cycle arrest and apoptosis, but also effectively suppresses tumor growth in xenograft mouse models. PROTAC BET Degrader-17 can be used to explore targeted therapies for acute myeloid leukemia.
(Pink: BET ligand (HY-169980); Blue: VHL ligand (HY-125845); Black: linker (HY-108369)).
For research use only. We do not sell to patients.
- CAS No.: 2409674-38-8
- Formula: C52H57F2N11O10S2
- Molecular Weight:1098.20
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
(Pink: BET ligand (HY-169980); Blue: VHL ligand (HY-125845); Black: linker (HY-108369)).
|
VHL |
BRD4 4.3 nM (IC50) |
BRD3 0.09 nM (DC50) |
BRD2 |
PROTAC BET Degrader-17 (Compound A12) inhibits the proliferation of MV4-11, RAMOS, K562 and Jurkat cells, with IC50 (72 h) values of 0.570 nM, 15.78 nM, 57.23 nM and 0.621 nM, respectively[1].
PROTAC BET Degrader-17 (0.1-300 nM; 15 min-24 h) induces the degradation of BRD2, BRD3 and BRD4 in a time- and dose-dependent manner, and downregulates c-Myc in MV4-11 cells[1].
PROTAC BET Degrader-17 (0.3-30 nM; 48 h) induces dose-dependent G1 cell cycle arrest in MV4-11 cells[1].
PROTAC BET Degrader-17 (0.3-100 nM; 48 h) induces dose-dependent apoptosis in MV4-11 cells, and exhibits superior potency over ABBV-075 (HY-100015) at concentrations below 10 nM[1].
PROTAC BET Degrader-17 exhibits excellent metabolic stability in mouse liver microsomes, with a half-life of 43.88 min and an intrinsic clearance rate of 31.59 mL/min/kg[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MV4-11 cells
-
Concentration:0.3-30 nM
-
Incubation Time:48 h
-
Result:Induced dose-dependent G1 phase cell cycle arrest; as the concentration of PROTAC BET Degrader-17 increased, the percentage of cells in G1 phase increased.
-
Cell Line:MV4-11 cells
-
Concentration:0.3-100 nM
-
Incubation Time:48 h
-
Result:Induced dose-dependent apoptosis; at lower concentrations (<10 nM), PROTAC BET Degrader-17 was more potent at inducing apoptosis than ABBV-075, though it did not achieve the maximal apoptotic induction level of A10.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude mice (4 to 5 weeks old)[1]
-
Dosage:2 mg/kg
-
Administration:i.p.; every other day; 21 days
-
Result:Achieved 60.5% tumor growth inhibition (TGI) relative to vehicle control.
Downregulated BRD4 and c-Myc protein expression in tumor tissue compared to vehicle control.
Caused no significant body weight loss during the study.
Chemical Information
-
CAS No. 2409674-38-8
-
Molecular Weight 1098.20
-
Formula C52H57F2N11O10S2
-
SMILES
O=C(C(N1)=CC(C(C2=CC(NS(=O)(CC)=O)=CC=C2OC3=CC=C(F)C=C3F)=CN4C)=C1C4=O)NCC5=CN(CCOCC(N[C@@H](C(C)(C)C)C(N6[C@H](C(NCC7=CC=C(C8=C(C)N=CS8)C=C7)=O)C[C@@H](O)C6)=O)=O)N=N5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- PROTAC BET Degrader-17
- 2409674-38-8
- PROTAC BET Degrader17
- PROTAC BET Degrader 17
- PROTACs
- Epigenetic Reader Domain
- Apoptosis
- ubiquitin-proteasome system
- BRD2
- acute myeloid leukemia cells
- BRD3
- MV4-11 cells
- VHL E3 ligase
- BRD4
- acute myeloid leukemia xenograft mouse models
- Jurkat cells
- RAMOS cells
- Inhibitor
- inhibitor
- inhibit